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Abstract. intestinal neuronal dysplasia type B (indB) is 
characterized by the malformation of the parasympathetic 
submucous plexus of the gut. it is generally accepted that 
indB has a genetic basis, and several genes produce an 
indB-like phenotype in mice when disrupted, such as 
EDNRB. however, no mutations associated with this disease 
have been identified in several series analysed. In the present 
studu, we sought to determine whether the EdnrB/Edn3 
signalling pathway plays a role in the pathogenesis of indB 
in humans. denaturing high performance liquid chroma-
tography (dhplc) techniques were employed to screen the 
EDNRB and EDN3 coding regions in 23 indB patients. in 
addition, association studies were performed on these genes 
with single nucleotide polymorphisms strategically selected 
and genotyped by Taqman technology. although several 
novel variants were detected in both genes, none of these 
variants appeared to play a functional role in protein function 
or expression. Our results indicate that additional screening 
of other candidate genes in larger patient series is required 
to elucidate the molecular basis of indB. additionally, the 
systematic lack of positive results in the screening of candi-
date genes for indB reported in the literature, together with 
our results, leads us to propose that indB may alternatively 
arise as a consequence of gain of function mutations in genes 
related to enteric nervous system development. therefore, the 
use of different molecular approaches, such as screening for 
genetic duplication or enhancer mutations, is recommended 
for future studies on the genetic basis of indB.
Introduction
intestinal neuronal dysplasia type B (indB; Omim 601223) 
is a malformation of the enteric nervous system (EnS) that 
accounts for over 95% of cases of isolated ind (1) and is char-
acterized by malformation of the submucosal plexus. children 
with indB present with intractable constipation and grossly 
slowed intestinal transit time. the histological features of 
indB include hyperplasia of the submucosal plexus, giant 
ganglia, ectopic ganglion cells at the muscular and mucosa 
layers, and increased acetylcholinesterase activity in the 
lamina propria and around submucosal blood vessels, which 
indicates immaturity of the EnS (1). the clinical picture 
of indB resembles hirschsprung disease (hScr; Omim 
142623), a congenital disorder characterized by the absence 
of intramural ganglion cells in the myenteric and submucosal 
plexuses along a variable portion of the distal intestine. indB 
does not include a region of aganglionosis, in absolute contrast 
to hScr, but as in hScr, it is reported to sometimes show 
increased extrinsic nerve fibers in the affected gut (2). In addi-
tion, some investigators have reported that 25-35% of patients 
with HSCR have associated INDB (2). The lack of unified 
criteria for the diagnosis of indB has led to doubt regarding 
whether indB exists as a distinct histopathology entity. 
moreover, the clinical features of indB are shared in common 
with immaturity of the EnS and arise in healthy individuals 
at an early age. however, a concerted effort has been made by 
scientists and clinicians to establish some generally accepted 
criteria for the diagnosis of indB (2). this has led to great 
advances in the understanding of its pathological basis. 
the etiopathogenesis of indB remains obscure. it is 
generally accepted that it is caused by a delay in EnS maturation, 
although its association with intestinal chronic obstruction and 
hScr indicates that it may arise as a secondary response to 
obstruction or inflammation of the bowel, either in the foetal 
or postnatal period (3). the genetic basis and congenital 
origin of indB were determined based on a study of affected 
monozygotic twins and on reports of families in which several 
members had biopsy-proven indB across multiple generations, 
although with no specific identified genetic alterations (4,5). 
Several genes have been described to play some aetiological 
role in hScr pathogenesis, usually related to the developmental 
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programme of neural crest cells (6). Since hScr and indB 
are EnS disorders that frequently occur in combination, 
common molecular pathways involved in the genesis of the two 
pathologies may exist. however, no mutations have been found 
in the most relevant genes implicated in hScr, such as RET 
and GDNF, in several indB patient series (7,8), or in other 
screened genes (5,9,10). By contrast, a certain combination 
of single nucleotide polymorphisms (Snps) in the RET proto-
oncogene was found to be associated with the indB phenotype 
in a previous study performed by our group (8). 
the mutation spotting lethal (sl) at Ednrb which, in homozi-
gosis, leads to aganglionosis in rats, provokes, in heterozygosis, 
hyperganglionosis and giant ganglia in the submucosal plexus 
(11). in addition, giant ganglia have also been observed in the 
aganglionic region of Edn3-deficient mice (12). The EDNRB 
and EDN3 genes have previously been evaluated as suscep-
tibility genes for INDB, with no mutations identified (7). 
However, the sensibility of the technique used was not suffi-
cient to completely exclude these genes as indB susceptibility 
factors. in addition, the absence of coding mutations in these 
genes does not rule out the existence of other variants that 
may confer susceptibility to indB, as is the case with the RET 
high-susceptibility-risk haplotype for hScr (13). the aim of 
the present study was to determine whether the EdnrB/Edn3 
signalling pathway plays a role in the pathogenesis of indB. 
to this end, a mutational screening of its coding sequence was 
conducted, and the identified polymorphisms and haplotypes 
were evaluated as susceptibility factors for this disease.
Patients and methods
the study comprised a total of 23 patients presenting with 
indB histologically diagnosed using the criteria updated 
by meier-ruge et al (2). Of note, one of the indB patients 
included in this series had a monozygotic twin, also affected 
by indB. 
triads composed of the patient and both parents were 
complete for 22 of the patients. in addition, a control group 
comprising 150 unrelated, race, age and gender-matched 
individuals, without any symptoms suggestive of EnS altera-
tions, was analyzed. informed consent was obtained from all 
the participants for clinical and molecular genetic studies. the 
study conformed to the tenets of the declaration of helsinki 
and was approved by the hospitales universitarios virgen del 
rocío irB. mutational screening was carried out by dena-
turing high performance liquid chromatography (dhplc) and 
sequence analysis, as previously described (14).
large-scale genotyping of EDNRB and END3 polymor-
phisms was performed in the indB triads and controls as 
previously described (14). allelic, genotypic and haplotypic 
frequencies and distributions were compared between patients 
and controls by SpSS version 15.0 for Windows. in addition, 
previously obtained data from 196 isolated hScr patients 
were used (14). In each analysis, statistical significance was 
calculated using pearson's χ2 test, with statistical significance 
set at α=0.05. haplotypes comprising the EDNRB and EDN3 
polymorphisms analysed were generated based on the results 
of the complete triads when available (patient, father and 
mother), which allowed us to reconstruct and compare the 
transmitted vs. non-transmitted alleles. With these results, we 
proceeded to compare the distribution of haplotypes among 
the patients and controls. Statistical estimates were calculated 
using the method outlined above.
Results
the mutational screening of the EDNRB and EDN3 coding 
regions in 23 indB patients revealed the presence of nine 
sequence variants, three of which had never been previously 
reported (table i). Since both the silent changes and intronic 
variants generate no variation at the protein sequence level, it 
was more probable that their pathogenic mechanism, if any, 
would operate by affecting transcript stability, rna splicing or 
DNA-protein binding. Thus, as a first approach, those variants 
were submitted to several splice site and transcription factor 
binding site sequence prediction interfaces (http://www.fruitfly.
org/seq_tools/splice.html; http://www.fruitfly.org/cgi-bin/seq_
tools/promoter.pl; http://www.ebi.ac.uk/asd-srv/wb.cgi). none 
of these variants were predicted to have any impact on the 
expression and maturation of mrna in silico. 
the most notable result was a heterozygous conserva-
tive substitution of serine to asparagine at codon 305 of the 
table i. Sequence variants detected in EDNRB and EDN3 mutational screening in indB patients. 
Gene nucleotide amino acid novel/previously allelic frequency in 
 change change described control population (%)
EDNRB
 c.732G>a t244t novel   0.5
 c.802-139a>G  novel   0.0
 c.802-122t>c  rs9530703   6.7
 c.831a>G l277l rs5351 56.5
 c.914G>a S305n rs5352   2.3
EDN3
 c.53-57c>t  novel   4.0
 c.365+23G>a  rs11570257   4.0
 c.621-80t>c  rs11570349   0.0
 c.*240delcc  rs34516274 28.5
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EDNRB gene in two independent patients. this variant was 
previously described in an hScr patient and was proposed to 
be a causative mutation due to the hypothetical disruption of 
a putative phosphorylation site and the absence of the variant 
in 50 control individuals tested (15). however, in the present 
study, we detected this variant in 5 out of 150 control individ-
uals in a heterozygous state. these results are in accordance 
with the available data on the genotypic frequency of S305n 
in a European population (http://www.ncbi.nlm.nih.gov/Snp). 
thus, it seems that the S305n variant is a rare polymorphism 
rather than a mutation related to hScr or indB.
the genotypic data of three EDNRB Snps (ivS1-
4125c>t, c.561c>t and c.*1985 G>a) and three EDN3 Snps 
(ivS2+7474t, ivS2-3935 c>G and ivS5+236 G>a) in the 
indB patients and controls were obtained using Taqman tech-
nology. these data, together with the available data from 196 
hScr patients previously obtained by our group (14), were 
used to analyse the allelic (table ii) and genotypic (table iii) 
distributions among the patient and control groups. no statis-
tical differences were found in the distribution of any of these 
variants or the generated haplotypes comprising them when 
indB patients were compared to hScr patients or when indB 
patients were compared to control individuals. additionally, no 
statistical differences were obtained in a transmission disequi-
librium test (tdt) analysis (data not shown).
Discussion
the pathogenesis of indB is not completely understood and 
its aetiology remains unknown, although several pieces of 
evidence suggest that it has a genetic basis. the presence of 
histological features characteristic of indB in murine models 
with heterozygous mutations at Ednrb and Edn3 (11,12) 
indicate that this signalling pathway may be implicated in the 
pathogenesis of indB, as is the case in hScr. however, the 
results presented here and in previous reports (7) fail to reveal 
any causal variant in IDNB patients. We also failed to find 
any association between Snps or the haplotypes comprising 
them and the disease. the lack of associations between indB 
and the EDNRB or EDN3 genes suggests that the endothelin 
signalling pathway is not implicated in the pathogenesis of 
this disease. however, the small patient sample presented here 
does not allow this hypothesis to be completely ruled out. in 
fact, a low number of patients is a recurring problem in the 
analysis of the genetic basis of idnB (5,7,9,10), due to the low 
prevalence of the disease and the difficulties involved in the 
clinical diagnosis and management of patients. 
Several animal models with mutations of various genes 
involved in EnS development, such as Hox1L11, Spry2, Ednrb 
and Edn3, share histological features with the indB pheno-
type in humans (11,16-18), suggesting that hyperganglionosis 
table ii. allelic distribution and frequency of EdnrB and Edn3 genotyped variants among patient and control groups. 
variant indB vs. hScr (%) indB vs. controls (%)
EDNRB
  c.484-4125 c>t
    c 37 (80.4) vs. 186 (84.5) 37 (80.4) vs. 170 (83.3)
    t 9 (19.6) vs. 34 (15.5) 9 (19.6) vs. 34 (16.7)
 χ2=0.40, p=0.5266483 χ2=0.22, p=0.63794669
  i187i
    c 46 (100) vs. 219 (99.5) 46 (100) vs. 202 (100)
    t 0 (0) vs. 1 (0.5) 0 (0) vs. 0 (0)
 Fisher's p=1 na
  c.+1985 G>a
    G 35 (87.5) vs. 188 (88.7) 35 (87.5) vs. 172 (86.0)
    a 5 (12.5) vs. 24 (11.3) 5 (12.5) vs. 28 (14.0)
 χ2=0.05, p=0.8302636 χ2=0.06, p=0.8014447
EDN3
  c.365+7474 t>c
    t 32 (66.7) vs. 154 (80.5) 32 (66.7) vs. 127 (63.5)
    c 16 (33.3) vs. 64 (19.5) 16 (33.3) vs. 73 (36.5)
 χ2=0.30, p=0.5866268 χ2=0.63, p=0.4262079
  c.366-3935 c>G
    c 37 (80.4) vs. 182 (75.9) 37 (80.4) vs. 176 (83.8)
    G 9 (19.6) vs. 38 (24.1) 9 (19.6) vs. 34 (16.2)
 χ2=0.14, p=0.7108324 χ2=0.31, p=0.5792162
  c.*231+236 G>a
    G 32 (69.6) vs. 169 (76.8) 32 (69.6) vs. 156 (83.9)
    a 14 (30.4) vs. 51 (23.2) 14 (30.4) vs. 30 (16.1)
 χ2=1.08, p=0.2978297 χ2=2.16, p=0.1415837
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in EnS could be due to defects in a variety of such genes, 
alone or in combination. For this reason, it would be useful 
to completely characterize the genetic background of patients 
with indB and to analyse whether different genes interact in 
order to increase the number of nerve cells and ganglia. Given 
the negative results obtained to date in studies of the molec-
ular causes of indB (5,7,9,10), we suggest the adoption of a 
completely new experimental approach to elucidate the genetic 
basis of indB. in this vein, animal models with deleted Bmp4, 
a protein implicated in EnS formation, present hypogangli-
onosis (19). it is tempting to speculate that the overexpression 
of Bmp4 protein may cause an increase in the number and size 
of enteric ganglia. in fact, overexpression of ntf3 promotes 
hyperplasia of the myenteric plexus in rats (20). in the same 
manner, we propose that indB arises as a consequence of gain 
of function mutations in genes related to EnS development. 
therefore, a different molecular approach to studying the 
genetic basis of indB, which includes screening for genetic 
duplications or enhancer mutations, may be required.
although the genetic basis of inBd remains to be eluci-
dated, it must be acknowledged that our results and those 
presented elsewhere (5,7,9,10) also support the possibility 
that indB is a secondary consequence of environmental 
factors, such as intestinal stenosis or intestinal obstruction 
(21). it is well known that individuals are not only a result of 
their genetic information, but also of interaction with their 
surrounding environment. despite the importance that intes-
tinal obstructive lesions may play in the indB phenotype, we 
believe that, before ruling out a genetic basis, it is necessary to 
completely analyse the genetic factors that may be associated 
with this disease by evaluating an adequate number of patients 
and by adopting alternative experimental approaches.
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